Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomarkers Conrado, D.J., et al.; “Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomar
Landscape analysis of biometric monitoring devices (BMDs) utilized in assessing cognition, sleep and mobility in Alzheimer’s disease and other age-related neurological diseases Kern, V.D., et al.; “Landscape analysis of biometric monitoring devices (BMDs) utilized in assessing cognition, sleep and mobili
The Coalition Against Major Diseases: Towards U.S. FDA qualification of hippocampal volume as a biomarker for enrichment in clinical trials for pre-dementia stages of Alzheimer’s disease Conrado, D.J., et al.; “The Coalition Against Major Diseases: Towards U.S. FDA qualification of hippocampal volume as a biomarke
The FDA is Listening: Integrating the Voice of the Patient in Drug Development for Parkinson’s and Huntington’s Diseases
The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease
Enabling Integration of Alzheimer Disease (AD) Prevention Study Data by Application of CDISC Standards: Extension to Biometric Monitoring Device (BMD) Assessments Arnerić, S.P., et al.; “Enabling Integration of Alzheimer Disease (AD) Prevention Study Data by Application of CDISC Standards:
The Coalition Against Major Diseases: Expanding its clinical trial database to support a disease progression model for pre-dementia Romero, K., et al.; “The Coalition Against Major Diseases: Expanding its clinical trial database to support a disease progressio